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Abstract	  	  
 The goal of this project is to engineer a benchtop model to test the efficacy of 
neutrophil blocking peptides, and provide a foundation for in vivo studies of peptide 
blocking. Current medical practices address the initial occlusion of heart flow by a 
surgical technique that re-opens the affected artery. If done early enough, this 
intervention can save what would otherwise be necrotic tissue; however, if sufficient 
time has elapsed, the reintroduction of blood flow to a now hypoxic environment may 
further harm otherwise healthy tissue. When deprived of oxygen for an extended period 
of time, the environment of the occluded vessel is primed for neutrophil invasion that 
results in damage to the surrounding tissue. 
 The introduction of blocking peptides that interrupt the neutrophil-endothelial cell 
interactions are promising as a therapy for decreasing the damage following 
reperfusion. Through disruption of neutrophil invasion, the tissue damage mediated by 
ICAM-1 and VCAM-1 endothelial cell membrane proteins can be minimized. In this 
project, we paired ICAM-1 and VCAM-1 blocking peptides with fluorophores to allow for 
physical and quantitative analysis of peptide binding. To test the specific efficacy of the 
peptide on endothelial cell proteins, we created ICAM-1 and VCAM-1 expressing cell 
lines to use as an in vitro test platform for both peptide and neutrophil binding. In future 
studies, our test platform will be paired with fluorescent microscopy and microfluidic flow 
chambers to test the binding efficiency of the peptide blockers and inhibition of 
neutrophil interactions. By doing so we have created an in vitro model to visualize the 
physical binding properties of peptide blockers and assess the impact of competitive 
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binding on neutrophil interaction. In addition, we developed a myocardial infarction and 
reperfusion model to pair visualization of peptide bonding with functional studies that 
test the beneficial effect. In this way we can correlate the amount of neutrophil blocking 
necessary to significantly improve heart function following the reperfusion treatment that 
accompanies myocardial infarctions. 
 Anticipated outcomes of this project were to engineer an in vitro testing platform 
to monitor neutrophil infiltration blocking, and to establish an in vivo model to analyze 
targeting peptides and their therapeutic outcomes. This was done through the utilization 
of peptides that target inflammation associated with cardiac disease, the pairing of said 
peptides with fluorophores that enable us to visualize the peptide interaction, and the 
use of microfluidic chambers to observe and quantify neutrophil binding and infiltration. 
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Introduction	  	  
Cross-Species Testing 
Current stagnant cell culture models and small animal studies face the ever-
present issue of incompatibility to human studies. When translated to the clinic, many 
suitable therapeutics fall short, in part due to the vast genetic and physiological 
differences between animal models and the intended human subject. It would be 
beneficial for both the scientific community and the patient population to have a testing 
platform that allows for simple compatibility testing across multiple species, thereby 
decreasing costly and time-consuming animal studies that fall short due to simple 
incompatibility errors. One approach to meeting this challenge is to engineer a bench-
top model that allows for quick multi-species testing of a single peptide molecule. In this 
project, we aim to create such a platform across mouse, pig, and human species, to 
quantify the binding efficiencies of a neutrophil blocking peptide to aid in damage related 
to cardiovascular regeneration. 
 
Cardiovascular Disease 
 Cardiovascular disease (CVD) is the leading cause of death for both men and 
women worldwide with many accompanying risk factors including old age, smoking, 
diabetes, high blood pressure, and chronic stress (1). CVD does not show 
discrimination across racial lines, with the risk factors similar across all demographics 
(2). One of the major contributors to CVD are Myocardial Infarctions (MI) and are 
defined as the interruption of blood supply to the heart caused by the blockage of a 
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coronary artery. This blockage results in a decrease in oxygen and nutrient supply to the 
affected area, essentially suffocating the tissue and causing irreparable damage. 
Without physician intervention, the affected cardiac tissue is replaced with non-
contractile scar tissue, rendering that portion of the heart useless for contraction and 
signal conduction (3). Established medical protocol calls for immediate surgical 
intervention, using balloon angioplasty to open the occluding vessel and allow for re-
introduction of blood flow to the site of injury. If done early enough, this intervention can 
be critical to saving the heart tissue; however, if enough time passes, reperfusion 
therapy results in myocardial damage due to neutrophil invasion (4, 5). 
 
Reperfusion Injury 
 The two major steps during an MI are the initial ischemia and the physician aided 
reperfusion. The ischemia occurs when an atherosclerotic plaque that has slowly been 
building in the inner lining of a coronary artery suddenly ruptures. This rupture results in 
thrombosis at the site, and obstructs blood flow downstream of the plaque (4). The 
detrimental outcome of this ischemia is a hypoxic environment at the location that is 
normally supplied by the artery. Therefore, the immediate goal of physician intervention 
is to open any blocked arteries, usually through the implementation of a stint at the site 
of plaque accumulation (6). If done early enough, this intervention can minimize muscle 
damage and the heart muscle may return at or near its pre-ischemic state with minimum 
damage (5). However, if sufficient time has passed between the initial blockage and 
stent implantation, a hostile environment is produced that is prime for damaging 
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neutrophil attacks (4, 7). When blood is reintroduced to this hostile environment, a 
cascade of negative effects promotes neutrophil invasion that mediates the death of 
potentially viable cardiomyocytes. This cascade is triggered by cytokines that are a part 
of the body’s inflammatory response and involves the endothelial cell layer surrounding 
the inner lining of the blood vessel (7, 8). 
 The stress on tissues that have been deprived of oxygen for an extended period 
of time results in the accumulation of chemically reactive molecules known as reactive 
oxygen species (ROS) (9). These molecules trigger a chemotaxis cascade within the 
vessel that ultimately results in the recruitment and infiltration of cell-damaging 
neutrophils into the cardiac tissue. During the ischemic phase of an MI, mast cells that 
are located in myocardial tissue degrade, releasing tumor necrosis factor-alpha (TNFα). 
This sudden TNFα release upregulates the expression of interleukin-6 (IL6) and 
interleukin-1 (IL1) in endothelial cells, which in turn increases the expression of 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1) on the surface of endothelial cells (4, 10). Upon reperfusion, neutrophils, the 
first responders of inflammation, are introduced to the site. In a separate but parallel 
cascade, the presence of ROS results in an activation of integrin beta-2 (CD18) and 
integrin beta-1 (CD29) on the surface of the neutrophils. These proteins pair with 
integrin alpha-L (CD11a) or integrin alpha-M (CD11b) and integrin alpha-4 (CD49d), 
respectively, to form lymphocyte function-associated antigen-1 (LFA-1) and very late 
antigen-4 (VLA-4) integrins. The integrins on the surface of neutrophils then react with 
ICAM-1 and VCAM-1 to promote the slowing, and eventual infiltration of neutrophils into 
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the heart tissue wall (Figure 1) (11-13). Instead of merely flowing through the site as 
they would through healthy vessels, the neutrophils react to markers on the endothelial 
surface and infiltrate into the tissue. Once present in myocardial tissue, the neutrophils, 
as part of their inflammatory response, react with and damage cardiomyocytes (7). It is 
this interface between neutrophils and endothelial cells that we aim to selectively inhibit 
through the use of peptide targeting to improve myocardial tissue outcome following 
reperfusion. 
 
Peptide Targeting 
 Therapeutic peptides have been used in a variety of contexts, from targeting 
malignant mitochondria in cancer cells to preventing eosinophilic infiltration into tissues 
in individuals with hypereosinophillic syndromes  (14, 15). These peptides are valuable 
for their ability to disrupt protein-protein interactions through direct competitive binding, 
a characteristic that is analogous to antibody binding therapies (16). What makes 
peptide therapy a more promising therapeutic avenue is the ability of peptides to be 
synthesized rather than expressed, allowing for greater control and larger scale 
production than corresponding antibodies. Furthermore, peptides have a greater target 
affinity compared to small molecules and there is no threat of immunogenic response 
that accompanies antibody-based therapies (17). It is for these reasons that we have 
chosen peptides to both protect myocardial tissue from damaging neutrophil invasion 
and as a tool for in vivo imaging of protein expression. 
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Figure 1: Chemotaxis cascade leading to neutrophil invasion of cardiac tissue. When 
introduced into a hypoxic environment, neutrophils tend to slow down, stick to, and infiltrate the 
endothelial wall of blood vessles (a). Mast cells degrade and release TNFa, causing upregulation 
of IL6 and IL1, and the increase of ICAM-1 and VCAM-1 expression on the surface of endothelial 
cells. Concurrently, when neutrophils are introduced to the low oxygen environment, they 
upregulate CD18 and CD29, which pair with CD11a/b and CD49d, respectively, to produce 
LFA1/Mac-1 and VLA-4. The interactions between LFA1/Mac-1 and ICAM-1, as well as those 
between VLA-4 and VCAM-1 are responsible for the infiltration of neutrophils across the 
endothelial cell layer and into the surrounding cardiac tissue (b). 	  
a.	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 Two peptides targeting endothelial membrane proteins have been developed and 
published: IP25 targeting ICAM-1 and VHSPNKK targeting VCAM-1 (18-25). Hindlimb 
ischemia studies have shown that IP25 reduces neutrophil infiltration by 56% and infarct 
size by 40% when injected either at the time of reperfusion, or 60m following reperfusion 
(18). Therapeutic studies on VHSPNKK have yet to be done; however, the peptide is 
homologous to VLA-4 and it has been proven to block neutrophil-endothelial interactions 
in vitro (19). Neither peptide has been used for imaging studies to visualize the ICAM-
1/VCAM-1 expression following reperfusion, and the direct effect that competitive 
blocking of these proteins may have on heart function during an MI and reperfusion. 
Furthermore, since these peptides have the capability of pairing with other molecules, 
they can provide a means of targeted therapy. The aim of this thesis is to use these 
peptides as a backbone to target inflammation associated with cardiac disease, to 
visualize this peptide interaction by pairing the peptides with fluorophores, and to stop 
neutrophils from binding and infiltrating the endothelial cell layer. 
 
Use of Fluorophores 
 Fluorophores are defined as a chemical compound that can re-emit light upon 
excitation at characteristic wavelengths (26). They are invaluable in imaging 
technologies including detection and quantification of protein interactions, differentiation 
between malignant and benign tumors, and monitoring of cell membrane diffusion and 
protein binding (27-30). In this project, fluorophores will be used as a method of 
detecting protein expression on endothelial cells following reperfusion, and in the 
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process, assess and quantify the neutrophil blocking properties of the peptides. We will 
be using two common fluorophores, enhanced green fluorescent protein (EGFP; 
excitement/emission spectrum of 488/509) and red fluorescent protein (DsRed; 
excitement/emission spectrum of 556/586). EGFP was chosen due to its inherently 
bright signal under conventional fluorescent microscopes whereas DsRed is more 
difficult to see in vitro, but due to its longer wavelength, penetrates deeper into tissues 
(26, 31-33). Both fluorophores are not phototoxic when illuminated in living cells, 
allowing for live cell imaging of tagged proteins (26).  
 Creation of peptide constructs with each fluorophore attachment will allow us to 
interchange them depending on the situation; EGFP for easy detection in vitro, and 
DsRed if in vivo detection proves difficult. We will use the molecular biology technique of 
DNA cloning to generate recombinant DNA that pairs the DNA sequence of fluorophores 
with those of peptides. Fluorophores are readily available in vector form, allowing for 
easy isolation and integration into a desired construct, and easy transfection into cell 
lines. 
 
DNA cloning 
 DNA cloning is a widely used and established recombinant DNA technique to 
quickly isolate, expand, and control protein production. In general, three specific steps 
are used in the technique; 1) restrictive enzyme sites are either introduced or utilized to 
act as complementary cleavage sites for multiple protein sequences, 2) ligation 
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reactions join together said sites, and 3) the constructed DNA is introduced to 
competent bacterial cells to induce the expression of a protein of interest. 
 Cloning vectors are typically used to accommodate the DNA of interest by acting 
as a backbone for the addition of external DNA sequences. The vectors are usually in 
the form of plasmids that contain a string of restrictive enzyme sites, termed the multiple 
cloning site (34). Restrictive enzyme sites are palindrome sequences that, when 
specifically recognized, are cleaved by enzymes to produce two complementary ends. 
These ends can then be paired with other DNA fragments that contain the same ends, 
essentially joining two otherwise separate entities into one cohesive chain, in a process 
known as ligation (35).  
 In a standard DNA cloning reaction, the circular, double stranded plasmid DNA is 
cleaved by a restriction enzyme. Concurrently, the DNA to be amplified is cleaved by 
the same restriction enzyme, producing complementary ends on both the plasmid and 
the desired DNA. The plasmid and desired DNA are mixed together with ligation 
enzymes, covalently joining the two together and producing a recombinant DNA 
plasmid. The new recombinant DNA plasmid, which now contains the DNA of interest, is 
then introduced into a host cell, typically a competent bacteria, by viral infection or 
transformation. The plasmid DNA typically contains antibiotic resistance, allowing host 
cells to proliferate under antibiotic stress and providing an avenue for selection of 
bacterial cells that contain the recombinant DNA plasmid. By nature, bacterial cells grow 
rather rapidly, and due to the autonomous replication of the plasmid DNA, we can 
induce the expression of the recombinant DNA plasmid to generate a large amount of 
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the desired protein. In such a way, recombinant DNA can be produced quickly, easily, 
with high purity, and with consistency	  (34).  
 
Overall Project 
 We have transfected cell lines to emit fluorescence upon ICAM-1 and VCAM-1 
expression. Additionally, we have paired fluorophores with peptide sequences that 
specifically bind to ICAM-1 and VCAM-1, providing the tools to image cell-to-peptide 
interaction with simple inverted microscopy techniques. With this foundation, we have 
been working to visualize the direct effect that peptide blocking has on neutrophil 
binding to ICAM-1 and VCAM-1 surface proteins. The study begins with simple co-
culturing techniques to assess the binding efficacy of the engineered peptides. We then 
take advantage of microfluidic flow chambers that mimic the blood flow within cardiac 
vessels to visualize the peptide-protein interaction, and how it changes under the added 
shear stress of blood flow. Furthermore, we will be able to introduce neutrophils into the 
system, to broaden our characterization of the constructed peptides to include the ability 
of the peptide to physically block the adhesion of neutrophils to the endothelial cell 
layer. The final step of the mouse studies will use an in vivo murine myocardial 
infarction and reperfusion model to test the physiological and functional results of our 
constructed peptides, and to visualize the homing, adherence, and efficacy of the 
constructs. Furthermore, we will create species-specific ICAM-1 and VCAM-1 
expressing cell lines to test the efficacy of the peptide across multiple species including 
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murine, porcine, and human, providing a simple, in vitro platform that decreases the 
chance of incompatibility when translated to the clinical setting. 
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Materials	  and	  Methods	  	  
Isolation of ICAM-1 and VCAM-1 sequences 
 Murine, porcine, and human specific sequences of ICAM-1 and VCAM-1 were 
obtained from a genome search. Primers were engineered to extract the desired 
sequence from cDNA synthesized from liver RNA using Protoscript AMV first strand 
cDNA synthesis kit (New England Biolabs).  Primers were constructed to flank the 
desired sequence with specific enzyme sites and insure proper enzyme cuts for the 
insertion into the pre-constructed vectors pEGFP-N1 (Clontech) or pDsRed-Monomer–
Hyg-1 (Clontech). Polymerase chain reaction (PCR) was done to amplify protein 
sequences from cDNA. Constructed forward and reverse primers were combined with 
dNTPs, Taq, and a buffer solution (Invitrogen) and run through a thermocycler with a 
run setting of a single 5m incubation at 94oC, followed by 30 cycles of 94oC for 15s, 
59oC for 30s, and 72oC for 1m, and a final single incubation for 7m at 72oC. After the 
run, the cycler was kept at 4oC until analysis. The solutions were then run on an SDS 
phage gel for separation and analysis. Sequences were sent to the DNA sequencing lab 
for confirmation. 
 
Enzyme cleavage and DNA ligation 
 Vectors to mammalian cells, pEGFP and pDsRed, were used as the backbone 
for incorporation of ICAM-1 and VCAM-1 sequences. Concentrations were measured 
with an Eppendorf BioPhotometer to determine the proper volumes necessary to reach 
a 3:1 ratio of vector to enzyme for restrictive enzyme cleavage. The vector and the 
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protein were incubated separately at 37oC for 2h with restrictive enzymes and their 
respective buffer solutions (New England Biolabs). The solutions were then PCR 
purified using a Qiagen spin purification kit to purify the DNA from the enzymatic 
reaction solution. The now cut vector and DNA sequences were added to a 
microcentrifuge tube along with T4 DNA Ligase, a 5x Ligase reaction buffer, and 
distilled water. The solution was incubated at 4oC overnight. PCR reactions and DNA 
sequencing were done for confirmation of ICAM-1 and VCAM-1 incorporation.  
 
Peptide/Fluorophore/His construction 
 pQE-2 (Qiagen), a vector for bacterial cells, was used as the backbone for the 
peptide/fluorophore vector. EGPF and DsRed sequences were extracted from pEGFP-
N1 (Clontech) and pDsRed-Monomer-Hyp-1 (Clontech) vectors, respectively. Previously 
discussed enzyme cutting and ligation techniques were used to insert the fluorophore 
sequence into the pQE-2 vector. The amino acid sequence of IP25 and VHSPNKK were 
determined from past publications. Two complimentary primers were formulated 
containing the entire amino acid sequence flanked by enzyme sites. To obtain the 
desired peptide, the two primers were annealed together by incubation for 1h at 3-5oC 
below the Tm of the primers. Again, enzyme cleavage and ligation techniques were used 
to insert the peptide into the previously constructed pQE-2/fluorophore vector, and PCR 
reactions and DNA sequencing were done to confirm the proper construction of the 
plasmid. 
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Transformation of Subcolony Efficiency DH5α competent E.coli 
 Subcolony Efficiency DH5α Competent E.coli cells (Invitrogen) were thawed on 
ice prior to transformation. 50µl of cells were transferred to 1.5ml microcentrifuge tubes. 
10-100pg of DNA was added to the cells and mixed gently. The cell/DNA mixture was 
incubated on ice for 30m, heat shocked in a 42oC water bath for 20s, then returned back 
to ice for 2m. 950µl of pre-warmed 1x LB media was added and incubated on a 225 rpm 
shaker in a 37oC warm room for 1h. Transformed cells were plated on pre-warmed 
selection plates containing either ampicillin (DsRed) or kanamycin (EGFP) and 
incubated overnight at 37oC. Transformed colonies could be determined by the naked 
eye due to the overproduction of fluorophores. 4 colonies were probed from each plate, 
and grown overnight in 1x LB media in 37oC in at 225 rpm. PCR reactions and DNA 
sequencing were performed to confirm proper insertion of the fluorophore. 
 
Isolation of 6xHis tagged peptide/fluorophore constructs 
 The peptide/fluorophore vector was isolated from bacterial cultures using a 
Qiagen QIA expression kit. A single colony was probed and grown in 250-500ml of 1x 
LB media overnight in 37oC on a 225 rpm shaker. The culture was spun down in 50ml 
increments until approximately 1g of total bacterial cell weight was achieved. A lysis 
buffer of 50mM NaH2PO4, 300 mM NaCl, 100mM imizadole solution adjusted to a pH of 
8.0 was added at 2 ml per g wet weight of bacteria. Lysozyme was added at 1 mg/ml 
and the solution was incubated on ice for 30m. After the incubation period, the solution 
was sonicated on ice with a sonicator equipped with a microtip, with six 10s bursts at 
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200-300W with a 10s cooling period between bursts. The lysate was centrifuged at 
10,000xg for 20-30m at 4oC to pellet cellular debris. The supernatant was collected, 
washed with LB buffer, and re-centrifuged. The supernatant was collected and used for 
column Ni-NTA column isolation.  
 The columns were prepared by mixing 1ml of 50% Ni-NTA slurry (Qiagen) with 
4ml cleared lysate (Qiagen) and mixed gently by shaking on a 200 rpm rotary shaker at 
4oC for 60m. The lysate-Ni-NTA mixture was loaded into a column system (Qiagen). 
The previously mentioned supernatant was loaded into the column mixture and the flow-
through was discarded. After all the supernatant was loaded, elution buffer (Qiagen) 
was run through the column to dissociate the 6xHis tag from the Ni-NTA matrix. The 
flow through was collected and placed in a Slide-A-Lyzer dialysis cassette (Thermo 
Scientific) to rid it of traces of imidazole. Dialysis was done in 1L of water at 4oC over 3 
rounds, with progressively longer incubation times of 2h, 5h, and overnight. At the 
conclusion of dialysis, peptide concentrations were determined by side-by-side 
comparison with a BSA standard curve. A QuantiPro BCA assay kit was used to give a 
linear response of protein concentrations. 
 
Transfection of CHO cell lines 
 An Amaxa Cell Line Nucleofector (Lonza) was used to transfect non-expressing 
Chinese Hamster Ovary (CHO) cells with the previously described protein/fluorophore 
constructs. Briefly, 1M CHO cells per treatment condition were counted, placed in a 
1.5ml eppendorf tube, and spun at 200g for 10m. The supernatant was aspirated off, 
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leaving a single pellet for each condition. 100µl of Solution V (Lonza) was added to re-
suspend the cell pellet. The cell suspension was then combined with 2µg of DNA and 
transferred into a Lonza certified cuvette, ensuring that the sample covered the bottom 
of the cuvette. Both high efficiency and high viability nucleofector programs were tested 
for each condition. 500µl of culture medium was quickly added to the cuvette at the 
termination of the program and the sample was gently transferred to a 24-well plate 
containing 1ml of pre-incubated culture medium. The cells were incubated in a 
humidified 37oC/5% CO2 incubator, and medium was changed every 3-4 days. To 
insure a stably expressing cell line, single cells were seeded in 96-well plates and 
allowed to grow into full colonies. 
 
Imaging 
 All cell-imaging of fluorophore expression was done using a Leica BMI 4000B 
inverted microscope. Fluorescent imaging of EGFP emission was done with a FITC filter 
cube with an excitation filter of 490/20, a dichromatic mirror of 505 and a suppression 
filter of 525/20. DsRed images were taken through a Texas Red filter cube with an 
excitation filter of 575/30, a dichromatic mirror of 600, and a suppression filter of 635/40. 
 
Neutrophil Isolation 
 Whole blood was obtained from healthy C57BL/6J mice. 3ml of blood was diluted 
into 5ml of HBSS without Ca++ or Mg++, and carefully layered over 3ml of Histopaque 
solution containing Ficoll and diatrizoate salts. The tube was centrifuged at 400g for 
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30m at 20oC. The supernatant was aspirated off and discarded, leaving just a loose cell 
pellet containing red blood cells (RBC) and neutrophils. The pellet was re-suspended in 
7ml of HBSS without Ca++ or Mg++ and mixed well. 7ml of dextran T500 in 0.9% NaCl 
was added to the solution, vortexed well, and allowed to sediment with gravity for 15-
20m. As soon as RBC-supernatant interface was visible, the supernatant was removed, 
transferred to new 50ml tube and spun at 1100 rpm for 10m. The supernatant was 
aspirated off and the pellet was re-suspended in 7ml of an ice-cold hypotonic solution of 
0.2% NaCL. After 30s, an ice-cold hypertonic solution of 1.6% NaCl was added to 
restore isotonicity. The solution was then spun at 1100 rpm for 10m, supernatant was 
aspirated off, and the pellet, now containing a pure neutrophil population, was re-
suspended in 2ml HBSS and set aside for neutrophil studies. A small amount of the 
neutrophil solution was smeared on a microscope slide and stained with a Differential 
Stain Kit (Newcomer Supply) to confirm neutrophil isolation. 
 
Myocardial Infarction/Reperfusion 
 Following a 5% isoflurane induction, Amidate was administered at 10mg/kg body 
weight.  Mice were intubated with a 20G angiocath tube and connected to a small 
animal ventilator set to 135 breaths per minute, through which 1.5% isoflurane was 
administered throughout the experiment. The mice were placed on a heating pad in the 
supine position, with the limbs taped in place.  The surgical area was cleared of fur with 
depilatory agent and sterilized by alternating betadine and 70% ethanol. An inch long 
vertical incision was made slightly to the right of center, over the ribcage.  Two muscle 
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layers were teased back and sutured in the retracted position.  An intercostal incision 
was made between the 3rd and 4th ribs and retractors were placed to expose the heart.  
A thin plastic reperfusion tube was placed at the site of the LAD, and a single 8-0 
monofilament suture was tied around the tube to occlude blood flow to the apex of the 
heart. The ribs were closed by the implementation of three sutures using a 6-0 
monofilament, insuring that the reperfusion tube remained accessible.  The muscles 
layers were then closed and sutured and the skin layer incision was closed, all using the 
6-0 monofilament suture and taking care to maintain access to the reperfusion tube. To 
insure minimal distress to the mice, a combination of 0.1mg/kg beuprinorphine was 
injected subcutaneously just prior to cessation of isoflurane. After 60m, the reperfusion 
tube was gently pulled from the animal, opening the occlusion and allowing blood to flow 
back to the affected region. Isoflurane administration was ceased before removing the 
tracheal tube from the mouse. Mice were observed until consciousness was reached, 
and every day thereafter. 
 
Echocardiogram Measurements 
 Functional measurements using a GE/Vingmed ultrasound Vivid 7 were taken 
prior to surgeries, as well as 1wk and 4wks post-surgeries to determine the 
development of heart damage. Mice were anesthetized with 4-5% isoflurane for 
induction of inhalation anesthesia using a chamber prior to echocardiography, and then 
2% isoflurane for maintenance anesthesia via nose cone. Skin was prepared with a 
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depilatory agent to remove fur and optimize ultrasound transmission. Ultrasound gel 
was placed on the transducer and scanning was performed. 
 M-mode images of left ventricular wall movement were recorded and internal 
ventricular septum thickness, left ventricular posterior wall thickness, and left ventricular 
internal dimension measurements were recorded. These values were used to calculate 
the end diastolic volume, stroke volume, and ejection fraction. 
 
Histology 
 At the termination of the study, hearts were collected, fixed in 5% formalin and 
processed with a Leica ASP300. The tissues were then embedded in paraffin molds 
using Leica EG1150H paraffin dispenser and Leica EG1150C cold plate. The samples 
were sectioned to 5 um thickness with a Leica RM2255 rotary microtome, and placed on 
microscope slides for staining. Collagen deposition was determined by Masson’s 
Trichrome staining. Briefly, paraffin slides were heated in a 60oC oven for 60m. Slides 
were deparaffinized by dipping in Xylene (3x), 100% EtOH (3x), 95% EtOH (1x) for 3m 
each, then rehydrated by a 3-5m bath in distilled water. Slides were transferred to 
Mordant in Bouin’s solution at 60oC for 60m, then washed in running tap water for 5m. 
Slides were incubated in Weigert’s Iron Hematoxylin working solution for 10m, followed  
by a wash in running tap water for 5m, and a quick rinse in distilled water. Slides were 
incubated in Biebrich Scarlet-Acid Fuchsin solution for 5m, followed by a rinse in 
distilled water, a 10m incubation in Phosphotungstic/Phosphomolybdic Acid and a 5m 
incubation in Aniline blue, followed by another rinse in distilled water and a 1m 
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incubation in 1% Acetic Acid. Dehydration and clearance of stains were done by 10 
quick dips in 95% EtOH followed by 10 quick dips in 100% EtOH. All slides were then 
mounted with Permount and a coverslip, and left to dry. 
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Results	  	  
Construction of fluorescently tagged peptides 
 The aim of our peptide molecule was three fold; 1) it must be produced in large 
quantities, 2) it must be easily purified, and 3) it must be easy to visualize by 
conventional means. A vector for bacterial cells, pQE-2, was used as the backbone for 
the construct. This was chosen primary due to its ability to easily grow within bacterial 
cells, and its 6xHis tag, which allows for easy purification using a simple Ni-NTA 
columnar isolation technique. Fluorescent sequences were excised from EGFP and 
DsRed specific vectors. Through enzymatic cleavage and ligation, the fluorophore 
sequences were inserted into the pQE-2 vector, obtaining the transition molecule that 
contains both a 6xHis tag and an accompanying fluorophore. The peptide sequence 
was determined from previously published data, and two complementary primers were 
created that, when fused together, produced the peptide amino acid sequence. 
Additionally, the peptides were created such that they were flanked by restrictive 
enzyme sites for insertion into the previously created fluorophore-tagged pQE-2 vector. 
Through another series of enzymatic cleavage and ligation reactions, the final plasmid 
construct consisted of a pQE-2 vector with a 6xHis tag, a fluorophore sequence, and a 
peptide sequence. When translated in bacteria, a plasmid attached to a fluorophore with 
an isolation tag was created (Figure 2).  
 The inherent capability of the pQE-2 plasmid to grow in bacterial cells insures 
that we have the capacity to create the peptide construct in large quantities with 
consistency between batches. Furthermore, the vector technique used in creation of the 
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a.	  
b.	   	  	  6xHis Tag Peptide 
EGFP 
c.	  
Figure 2: His-fluorophore-peptide construction. A series of PCR reactions to amplify 
desired sequences, were paired with enzyme cleavage and ligation reactions to produce his-
fluorophore-peptide constructs. (a) Fluorophore sequences (EGFP) were excised by enzyme 
cleavage from commercially available fluorophore vectors and inserted into the multiple 
cloning site of a pQE-2 vector. (b) The amino acid sequence of the desired peptide (IP25) 
was mapped out and primers were created so as to flank the sequence with enzyme sites 
that could be used to insert the desired peptide into the remaining multiple cloning sites, 
resulting in the final construct. (c) A schematic representation of the translated sequence. 	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peptide provides the opportunity to switch out the fluorophore with a molecule that has 
shown to have beneficial effects on minimizing inflammatory responses. This invites the 
prospect of creating an ICAM-1 or VCAM-1 targeting therapeutic that is aggressive in its 
treatment of reperfusion injury instead of a peptide that is merely defensive in nature. 
 
Translation of fluorescently tagged peptides 
 The plasmid was inserted into competent bacterial cells for high yield translation 
of the desired peptide. The bacteria were cultured on selective media to isolate the 
positively transfected colonies. Due to the translation of attached fluorophores, 
successful transfection was with the human eye as colonies possessing brightly colored 
properties. These colonies were probed and plasmid composition was determined 
through PCR analysis and DNA sequencing. Probed colonies were further grown as 
overnight cultures to produce the desired peptide-fluorophore-his construct in large 
quantities. The cells were then collected and lysed to collect the peptide constructs. The 
6x His tag was utilized for isolation by a Ni-NTA column. Again, successful isolation was 
seen by the naked eye due to the brightly colored properties of the fluorophore. Finally, 
concentration studies comparing the absorbance of the peptide to that of a BSA 
standard control were done to quantitatively determine the amount of peptide that was 
isolated from culture (Figure 3). These isolated peptides will be used for in vitro and in 
vivo studies of peptide binding to ICAM-1 and VCAM-1 endothelial membrane proteins, 
and the effect that competitive binding has on neutrophil interactions. 
	   23	  
 
 
 
 
a. b. 
c.	  
Figure 3: His-fluorophore-peptide growth and isolation. Competent E.coli were 
transfected with bacteria specific pQE-2 vectors for large-scale translation of the constructed 
his-fluorophore-peptide vector. a) The upregulation of fluorophore production made for easy 
identification of transfected colonies. b) The poly-his tail was used for isolation using an Ni-
NTA columnar system. During the isolation, a fluorophore gradient could be seen by the 
naked eye as the 6xHis tags were covalently binding to the Ni-NTA beads. c) BSA studies 
were done on EGFP-tagged peptides to determine the concentration of isolated peptide 
based on its absorbance properties. 	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Fluorescent emitting ICAM-1 and VCAM-1 expressing CHO cell lines 
 In order to quickly check the binding of peptide constructs to their target proteins, 
we developed cell lines that emit fluorescence upon expression of ICAM-1 and VCAM-1. 
ICAM-1 and VCAM-1 sequences were obtained through an online protein search on 
NCBI. These sequences were then analyzed and compared to that of the fluorophore 
vector to determine which restriction enzyme sites could be used without the hazard of 
cleaving functional sequences. With this, primers were engineered to flank the desired 
protein sequence while adding on restriction enzyme sites for easy insertion into the 
desired fluorophore vector. Restriction enzyme cleavage and ligation techniques were 
used to insert the base pair sequences of ICAM-1 and VCAM-1 proteins into EGFP and 
DsRed peptide vectors (Figure 4). Care was taken to insure that base pairs aligned 
such that the translation of the sequence resulted in expression of both the protein and 
the fluorophore.  
 
 
	  
ICAM-1 (1.6bp) 
Figure 4: Protein/fluorophore construction. ICAM-1 (and VCAM-1) sequences were 
isolated and expanded using engineered primers that flanked the sequences with 
restrictive enzyme sites. These sites were used for insertion into the multiple cloning 
sequence of commercially available EGFP (and DsRed) vectors. 	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 ICAM-1 and VCAM-1 sequences were extracted from cDNA using the 
aforementioned primers and run on PCR for conformational analysis (Figure 5). 
Following mutual enzyme cleavage and ligation, the vectors were introduced into 
competent bacterial cells for rapid duplication. Multiple colonies were probed, grown 
overnight, and checked for vector induction. This was done through PCR reactions with 
the same primers. If the vector was present in the bacterial cells, PCR reactions with the 
flanked primers should yield bands at the same base pair length as the desired protein 
sequence (Figure 5). As a second check, we performed PCR reactions with primers  
 
 
 
 
from both the protein sequence and the fluorophore vector instead of the original 
primers that flanked the ICAM sequence. For example, the NheI forward primer that sits 
on the beginning of the Pig ICAM vector was paired with an EGFP reverse primer that 
lies in the middle of the EGFP sequence. In such a way we can check the total length of 
the vector in addition to the individual aspects of the constructed (Figure 6).  The final 
Figure 5: PCR confirmation of ICAM isolation and insertion into EGFP vector. 
When run on an SDS-PAGE gel, bands were seen at approximately 1600 bp, 
consistent with the length of the ICAM sequence, at both the initial isolation of ICAM 
from cDNA (a) as well as within the EGFP vector (b), suggesting proper insertion of 
ICAM within the desired fluorophore vector. Duplicates of 10x and 100x template 
concentrations were run for each PCR for quality assurance. 
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check for proper DNA insertion was performed through cleavage with restriction 
enzymes that sat at the beginning of the inserted sequence and somewhere along the 
sequence itself. This allowed us to check the presence of the restriction enzyme site 
that was introduced via the engineered primers, as well as the integrity of the inserted 
peptide and the overall length of the complete peptide (Figure 6). In short, PCR 
conformational testing was done through the use of primers that flank the inserted 
sequence as well as those that began within the fluorophore sequence. Furthermore, 
 
enzyme cleavage was performed to determine that the location of the restriction enzyme 
sites matched those expected of the constructed vector, and that we maintained the 
integrity of the vector as a whole. This insures that proper insertion of the protein 
complex was achieved, and these results were professionally sequenced to 
unequivocally verify the final construct. 
Figure 6: Enzyme cut of Pig ICAM-EGFP construct. Three colonies were chosen to test 
for proper DNA insertion. The left samples show PCR results from duplicate samples run with 
primers that flank the desired sequence. Bands are seen at the length of the pig ICAM 
sequence (1614 bp). Samples on the right show the result of enzyme cleavage with NheI, 
which was introduced within the forward primer sequence, and HindIII, which is naturally 
located in the middle of the Pig ICAM sequence. Bands were seen at 5165 bp and 1118 bp, 
consistent with proper insertion.  
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 Upon successful creation of protein-fluorophore constructs, the peptide was 
delivered into Chinese Hamster Ovary (CHO) cells via transfection. CHO cells were 
used due to their lack of ICAM-1 and VCAM-1 expression, their rapid growth, and their 
high protein production. Due to the nature of the construct, ICAM-1 and VCAM-1 
expression were accompanied by light emission under either FITC or Texas Red 
wavelengths. After 48d in culture, cells were imaged with fluorescent microscopy to 
determine which cells resulted in positive transfection. To insure a stably expressing cell 
line, we seeded single cells and allowed them to grow to full cultures. This resulted in 
confluent cultures with 100% expression of the desired protein (Figure 7). As stated 
earlier, both ICAM-1 and VCAM-1 constructs specific for human, pig, and mouse 
species are currently underway. 
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Figure 7: ICAM-1 expressing CHO cell line: Non-expressing CHO cells were transfected 
with ICAM-1-EGFP vectors. Confirmation of transfection was done by the imaging of cells 
under an inverted microscope equipped with fluorescence filtration cubes. Single cells were 
isolated from the culture and let grow to obtain a pure ICAM-1 expressing cell culture. 	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Murine myocardial infarction/reperfusion model 
 A murine myocardial infarction/reperfusion model was established for in vivo 
studies of peptide binding. To emulate an infarction/reperfusion, the left anterior 
descending artery (LAD) was targeting for occlusion. In a murine model, LAD is rather 
difficult to define due to the fact that it is embedded within the myocardial tissue. To test 
for proper ligation positioning, a small suture was placed at the estimated location of the 
LAD Histological results were obtained at 1wk post ligation from both control and 
infarcted mice. In addition to wall thinning of the left ventricle, collagen deposition can 
be seen, indicating muscle depletion and scar tissue formation downstream of the 
ligated LAD. The reconstruction of the heart tissue is accompanied by a decrease in 
ejection fraction, as was calculated from echocardiogram ultrasound measurements 
(Figure 8). Taken together, these results indicate successful LAD identification and 
competence in the infarction/reperfusion surgical technique. 
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c. 
Figure 8: Scar tissue and ventricle thinning indicative of successful LAD ligation. 
Ultrasound images of left ventricular beating before (a) and after (b) LAD occlusion. A 
decrease in heart wall movement can clearly be seen post-infarction. Massons Trichrome 
staining results 1wk post-surgery (c). Red (muscle, cytoplasma, fibrin), Blue (collagen), 
Yellow (erythrocytes). Percent change in ejection fraction (EF) calculated as the change in 
EF 1wk post-surgery as a fraction of the measured EF prior to surgery.  	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Future	  Work	  
 
 With the successful isolation of a mouse ICAM-1 expressing cell line and a 
DsRed emitting IP25 peptide, enough preliminary work has been done to begin in vitro 
testing of peptide binding. The initial testing will compare the binding properties of the 
peptides with both ICAM-1 expressing and non-expressing cells. A cell population 
expressing EGFP upon ICAM-1 activation will be cultured to confluence and incubated 
with peptides linked to DsRed. If selective binding occurs, a combined image will show 
an overlay between green and red wavelengths (Figure 9). Further binding efficiency 
studies will be done using flow cytometry analysis. Through the use of two different 
emission wavelengths, flow cytometry will allow us to quantitatively measure the 
percentage of peptides that bind to ICAM-1 expressing cells. The data obtained from 
these in vitro studies will be incorporated into further in vivo studies. 
 Once correct binding has been confirmed and quantified, we will insure that the 
peptide constructs are interfering with neutrophil attachment. Through a flow cytometry 
chamber, ICAM-1 expressing cells will be cultured to confluence within the chamber and 
peptide constructs will be given a chance to interact with the cells. After sufficient 
interaction, neutrophils labeled with a membrane dye will then be flowed over the 
cell/peptide complex and analyzed for adhesion properties. A flow chamber setup is 
ideal not only in its similarity in scale to blood vessels, but also its introduction of forces 
that mimic those that are inherent in blood flow. For more quantitative analysis, flow 
cytometry will be done to measure the exact percentage of neutrophils that do and do 
not adhere to and interact with peptide blocked ICAM-1 presenting cells. 
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 In vitro competitive blocking of neutrophil attachment will provide sufficient 
evidence to proceed with in vivo studies using a murine model for myocardial infarction 
and reperfusion. Following reperfusion, targeting molecules will be injected through the 
tail vein of the mouse and the binding of the neutrophil inhibitors will be analyzed. Due 
to the thin skin of the mouse, the overall binding properties of the peptide-fluorophore 
constructs can easily be visualized using commercial microscopes, such as the Maestro 
imaging system from PerkinElmer. Efficacy of the targeting peptides will be determined 
by overall survival of the mice, and calculations including the left ventricular ejection 
fraction and the end diastolic volume. Furthermore, at the termination of the study, the 
heart organs of each animal will be excised and measured for infarct size, collagen 
EGFP-­‐ICAM-­‐1	  transfected	  Cho	  cells His-­‐DsRed-­‐IP25 
	   	  
Figure 9: In vitro testing of construct binding and neutrophil blocking: To test the 
binding and blocking properties of the isolated his-fluorophore-peptide constructs, ICAM-1 
expressing CHO cells will be grown in a confluent layer. IP25-DsRed peptides will be co-
cultured with the cells, and overlap between the two emission spectrums will be analyzed. If 
binding is seen, the setup will be repeated but in a microfluidic flow chamber in which labeled 
neutrophils will be rushed over the cell/peptide layer and analyzed for adherence. 	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deposition, and infiltration of inflammatory cells. These in vivo studies will give us a 
measurable understanding of the role that ICAM-1 and VCAM-1 play on post-
reperfusion heart patients. 
 It is well documented that a number of promising therapeutics inevitably fall short 
when expanded to human clinical trials due to unforeseen incompatibility issues. Slight 
variations in DNA sequence and protein folding do not necessarily insure identical 
binding of the peptide in question to its desired protein. For example, the base pair 
length of the same ICAM-1 protein varies from 1614 in mice, to 1613 in pigs, to 1599 in 
humans. Such small variations can lead to vast consequential results when it comes to 
the binding of a small, 9 amino acid long peptide. It is thus in the best interest of the 
scientist, patient, and medical community to engineer a platform that allows for rapid, 
cross-species testing. It is in the realm of this thesis to create a multi-species analysis to 
test the efficacy of the same peptide-fluorophore construct in three parallel models; that 
of the mouse, pig, and human. In order to create a multi-species platform for peptide 
testing, further work needs to be done to pair fluorophores with species-specific ICAM-1 
and VCAM-1 sequences from. By having a multi-species platform, we can test the 
efficacy of peptide blocking on the same protein in a variety of animals. This will allow 
us to incrementally increase from an in vivo mouse model, to that of a pig, and 
ultimately to that of human clinical trials, all the while having an in vitro foundation for 
extrapolation purposes. The in vitro platform will decrease the need for animals while 
increasing the relevancy of the therapy. In such a way we can quickly categorize the 
binding affinity of the same protein through flow chamber analysis, and quickly provide a 
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foundation for in vivo animal studies. Furthermore, we will be able to decrease the 
invested time in a particular therapeutic that fails to translate to larger animal models, 
decreasing the cost and life investment in therapeutics that are bound to fail. 
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Conclusions	  	  
 Peptide binding is a promising avenue for decreasing damage following a 
myocardial infarction and reperfusion injury. By selectively blocking the interaction 
between neutrophils and surface proteins, we can diminish the inflammatory response 
and subsequent myocyte mortality, leading to a favorable outcome for patients after 
enduring such a debilitating event. Due to the nature of our constructs, it would be an 
easy transition from imaging peptide binding to functionally adding remedial agents to 
localize delivery of effective therapeutics. For instance, it is within the realm of the 
methods described to pair the ICAM-1/VCAM-1 targeting peptides with IL-10, a protein 
that plays a protective role through the suppression of the acute inflammatory response. 
In such a way, we can create a directed treatment that is beneficial to the tissue instead 
of merely defensive in nature, not only preventing myocardial necrosis, but aiding the 
tissue to heal itself. 
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